BIVI
NASDAQBiovie
$1.00
-0.35 (-25.98%)
2026-08-07 00:00
Healthcare
Biotechnology
--
--
Short Interest (1 Year)
% of Volume Sold ShortMarket Cap
$10.3M
P/E Ratio
N/A
52W Low
52W High
$0.82
$2.31
Volume
2.1M
Analyst Rating
Hold
Target: $10
10 Analyst Ratings
Strong Buy
0
Buy
0
Hold
10
Sell
0
Price Target Range
Low: $5
Avg: $10
High: $12
About Biovie
BioVie Inc., a clinical-stage biopharmaceutical company, develops drug therapies to treat neurological and neurodegenerative disorders, and advanced liver disease in the United States. The company develops BIV201, that is in phase 2 for the treatment of ascites due to chronic liver cirrhosis. It also develops NE3107 that is in Phase III clinical trial for the treatment of patients with mild to moderate Alzheimer's disease; and in Phase 2 clinical trial to treat Parkinson's disease, as well as fo...
Employees
13
Website
bioviepharma.com
Financial Highlights
Annual
Quarterly
| Year | Revenue | Op Margin | Net Income | Free Cash Flow |
|---|---|---|---|---|
| 2025 | N/A | N/A% | -$17.5M | -$19.0M |
| 2024 | N/A | N/A% | -$32.1M | -$27.9M |
| 2023 | N/A | N/A% | -$50.3M | -$40.3M |
| 2022 | N/A | N/A% | -$26.1M | -$19.0M |
| 2021 | N/A | N/A% | -$130.2M | -$10.5M |
| 2026 Q1 | N/A | N/A% | -$5.3M | -$7.4M |
| 2025 Q4 | N/A | N/A% | -$6.1M | -$4.4M |
| 2025 Q3 | N/A | N/A% | -$5.1M | -$3.0M |
| 2025 Q2 | N/A | N/A% | -$3.5M | -$5.6M |
| 2025 Q1 | N/A | N/A% | -$2.8M | -$1.3M |
| 2024 Q4 | N/A | N/A% | -$7.1M | -$8.6M |
| 2024 Q3 | N/A | N/A% | -$4.2M | -$3.6M |
| 2024 Q2 | N/A | N/A% | -$4.9M | -$4.0M |